X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Torrent Pharma with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs MYLAN (US) - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 TORRENT PHARMA   MYLAN
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
MYLAN
Dec-14
TORRENT PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,7683,867-   
Low Rs1,1862,725-   
Sales per share (Unadj.) Rs346.11,324.0-  
Earnings per share (Unadj.) Rs55.2159.5-  
Cash flow per share (Unadj.) Rs73.3256.7-  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs257.1658.1-  
Shares outstanding (eoy) m169.22378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x4.32.5 171.4%   
Avg P/E ratio x26.820.7 129.5%  
P/CF ratio (eoy) x20.112.8 156.9%  
Price / Book Value ratio x5.75.0 114.7%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m249,8871,247,263 20.0%   
No. of employees `00011.825.0 47.1%   
Total wages/salary Rs m9,9340-   
Avg. sales/employee Rs Th4,971.520,038.0 24.8%   
Avg. wages/employee Rs Th843.20-   
Avg. net profit/employee Rs Th792.42,413.9 32.8%   
INCOME DATA
Net Sales Rs m58,569500,951 11.7%  
Other income Rs m2,233-2,920 -76.5%   
Total revenues Rs m60,802498,031 12.2%   
Gross profit Rs m13,773124,589 11.1%  
Depreciation Rs m3,06936,793 8.3%   
Interest Rs m2,05621,608 9.5%   
Profit before tax Rs m10,88163,268 17.2%   
Minority Interest Rs m0-260 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5452,660 58.1%   
Profit after tax Rs m9,33660,348 15.5%  
Gross profit margin %23.524.9 94.6%  
Effective tax rate %14.24.2 337.7%   
Net profit margin %15.912.0 132.3%  
BALANCE SHEET DATA
Current assets Rs m53,841440,402 12.2%   
Current liabilities Rs m31,612344,306 9.2%   
Net working cap to sales %38.019.2 197.9%  
Current ratio x1.71.3 133.2%  
Inventory Days Days9778 124.5%  
Debtors Days Days84107 78.1%  
Net fixed assets Rs m42,079115,894 36.3%   
Share capital Rs m84617,715 4.8%   
"Free" reserves Rs m42,6550-   
Net worth Rs m43,501249,022 17.5%   
Long term debt Rs m22,408372,014 6.0%   
Total assets Rs m101,2501,003,037 10.1%  
Interest coverage x6.33.9 160.2%   
Debt to equity ratio x0.51.5 34.5%  
Sales to assets ratio x0.60.5 115.8%   
Return on assets %11.38.2 137.7%  
Return on equity %21.524.2 88.6%  
Return on capital %19.613.6 144.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m14,7620-   
CASH FLOW
From Operations Rs m10,12765,850 15.4%  
From Investments Rs m-7,869-51,931 15.2%  
From Financial Activity Rs m-1,918-17,352 11.1%  
Net Cashflow Rs m212-3,433 -6.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare TORRENT PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare TORRENT PHARMA With: PIRAMAL ENTERPRISES  GLENMARK PHARMA  FRESENIUS KABI ONCO.  JUBILANT LIFE SCIENCES  STRIDES SHASUN LTD  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - DR. REDDYS LAB COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS